Term ended Nov 23, 2025 · High confidence
20-year base term ended Nov 23, 2025
USPTO later recorded it as expired for non-payment on Sep 7, 2026.
Held by Adamas Pharmaceuticals, Inc.
Filed Aug 2, 2013 as application 13/958,153 · Granted Aug 5, 2014
Base term, 20 years from filing
Today
Term ended Nov 23, 2025
2005
2026
Clock starts
Nov 23, 2005
Nov 23, 2005
Term ended
Nov 23, 2025
Nov 23, 2025
Granted
Aug 5, 2014
Aug 5, 2014
base term
after the term ends
fee events
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 8,389,578, to Nov 23, 2025. The term already ends on or before that date, so the cap shortened nothing.
2 of 2
Maintenance fees paid
Two maintenance fees can end this term early, the ones due 3.5 and 7.5 years from grant; the third one's grace period runs past the term end. This counts the ones the record shows paid.
24
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Nov 23, 2005, when application 11/286,448, the earliest non-provisional in its chain, was filed (this one was filed Aug 2, 2013) | Nov 23, 2025 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 8,389,578) | resolves to Nov 23, 2025, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 2 of 2 maintenance fees paid | term ended | High confidence |
| USPTO status record | Recorded as expired for non-payment on Sep 7, 2026, after the term ended | no change | High confidence |
| Computed term end | The steps above, in order | Nov 23, 2025 | High confidence |
This family
| US 8,389,578 | In force Jan 2028 | Jan 2028 |
| Application 13/756,275 | Abandoned not computed | not computed |
| US 8,796,337 | this patent Nov 2025 | Nov 2025 |
| US 8,895,614 | Term ended no later than Nov 2025 | no later than Nov 2025 |
| US 8,987,333 | Term ended no later than Nov 2025 | no later than Nov 2025 |
| US 8,895,618 | Term ended no later than Nov 2025 | no later than Nov 2025 |
| US 8,889,740 | Term ended no later than Nov 2025 | no later than Nov 2025 |
| US 8,895,617 | Term ended no later than Nov 2025 | no later than Nov 2025 |
8 of 24 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Aug 6, 2013 Reel 30953, frame 535 | Went, Gregory T.; Fultz, Timothy J.; Porter, Seth; Meyerson, Laurence R.; Burkoth, Timothy S. | Adamas Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
| Jun 6, 2017 Reel 42704, frame 254 | Adamas Pharmaceuticals, Inc. | Adamas Pharma, LLC | Assignment of Assignor's Interest |
| Nov 28, 2017 Reel 44234, frame 190 | Went, Gregory T.; Fultz, Timothy J.; Porter, Seth; Meyerson, Laurence R.; Burkoth, Timothy S. | Neuromolecular Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
| Nov 28, 2017 Reel 44900, frame 215 | Neuromolecular Pharmaceuticals, Inc. | Adamas Pharmaceuticals, Inc. | Change of Name |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
Terminal disclaimer
A terminal disclaimer resolved from the filed document, referencing US 8,389,578, ends no earlier than this term, so it caps nothing.
Citations
44
later US patents cite this one
That is top 25% of utility patents granted in 2014 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.